Arf6 as a therapeutic target: Structure, mechanism, and inhibitors.
10.1016/j.apsb.2023.06.008
- Author:
Dejuan SUN
1
;
Yuanyuan GUO
1
;
Piyu TANG
1
;
Hua LI
1
;
Lixia CHEN
1
Author Information
1. Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
- Publication Type:Review
- Keywords:
Arf6;
Drug resistance;
Inhibitors;
Mechanism;
Structure
- From:
Acta Pharmaceutica Sinica B
2023;13(10):4089-4104
- CountryChina
- Language:English
-
Abstract:
ADP-ribosylation factor 6 (Arf6), a small G-protein of the Ras superfamily, plays pivotal roles in multiple cellular events, including exocytosis, endocytosis, actin remodeling, plasma membrane reorganization and vesicular transport. Arf6 regulates the progression of cancer through the activation of cell motility and invasion. Aberrant Arf6 activation is a potential therapeutic target. This review aims to understand the comprehensive function of Arf6 for future cancer therapy. The Arf6 GEFs, protein structure, and roles in cancer have been summarized. Comprehending the mechanism underlying Arf6-mediated cancer cell growth and survival is essential. The structural features of Arf6 and its efforts are discussed and may be contributed to the discovery of future novel protein-protein interaction inhibitors. In addition, Arf6 inhibitors and mechanism of action are listed in the table. This review further emphasizes the crucial roles in drug resistance and attempts to offer an outlook of Arf6 in cancer therapy.
